User: Guest

  



DOMAIN EXPERT ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

8816

Interactions with Platform & by Email *

INTERACTIONS

1234

Unique # Participated *

PARTICIPANTS

264

Responses Validated *

VALIDATIONS

52

* Platform engagements are dynamic. Stats are published quarterly.


  •  CODE

  •  PAGES

  •  DATE

  •  PRICE

    $

  •  DATA EXHIBITS

    125


TABLE OF CONTENTS


   Pages :    | $

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Quantitative Techniques & Analytics.....I-3
Product Definition and Scope of Study.....I-3
Rheumatoid Arthritis.....I-3
  
   Multiple Sclerosis.....I-4
Psoriasis.....I-4
Crohn's disease.....I-4
  
   Autoimmune Disease Therapeutics Market Continues to Flourish.....II-5
Pharmaceutical Industry Hit by Economic Downturn.....II-5
1$100
   Economic Downturn Takes Toll on R&D.....II-6
Current and Future Analysis.....II-6
Segment Analysis.....II-6
1$100
   Rheumatoid Arthritis Therapeutics – The Largest Segment.....II-7
Multiple Sclerosis Therapeutics Market.....II-7
Crohn’s Disease Therapeutics Market.....II-7
1$100
   Ulcerative Colitis Drugs Market.....II-81$100
   Biologics Find Acceptance as First Line of Treatment for Autoimmune Diseases.....II-9
High Unmet Need Favors Growth.....II-9
Impact of Biosimilars Legislation on Biologic Arthritis Drugs Market.....II-9
1$100
   New Products to Drive Market Growth.....II-10
Biogenerics to Expand Adoption of Biological Drugs.....II-10
Risk of Cancer Due to Anti-TNF Drugs.....II-10
1$100
   Superior Outcomes to Enhance Adoption of Biologics.....II-11
Efficacy and Convenience – Key Factors Driving Physician’s Decision.....II-11
1$100
   Immunity and Immune System.....II-12
Autoimmune Diseases.....II-12
Women- Highly Susceptible to Autoimmune Diseases.....II-12
1$100
   Table 1: Percentage Breakdown of Incidence of Autoimmune Diseases in Men and Women (includes corresponding Graph/Chart).....II-131$350
   Complexity in Manifestations Renders Difficulty in Understanding the
  Conditions.....II-14
Etiology of Autoimmune Diseases.....II-14
Genetic Predisposition.....II-14
1$100
   Environmental Factors.....II-15
Autoimmune Diseases – A Social and Health Burden.....II-15
Regulatory Glitches and High Costs Hinder Biogenerics.....II-15
1$100
   Types of Autoimmune Diseases.....II-16
Incidence and Prevalence.....II-16
1$100
   Diagnosis and Treatment of Autoimmune Diseases.....II-17
Overview on Select Biologic Drugs.....II-17
Remicade.....II-17
1$100
   Humira.....II-18
Rituxan® (rituximab).....II-18
Cimzia.....II-18
1$100
   Cimzia to Face Stiff Competition in Rheumatoid Arthritis Market.....II-19
Psoriasis – A Promising Market for Cimzia.....II-19
1$100
   Actemra.....II-20
Enbrel.....II-20
1$100
   Rheumatoid Arthritis.....II-21
Disease Overview.....II-21
Low Penetration to Sustain growth of Anti-TNF Drugs.....II-21
Incidence and Prevalence Higher in Urban and Developed Regions.....II-21
1$100
   Symptoms and Diagnosis.....II-22
Treatment of Rheumatoid Arthritis.....II-22
BRMs Revolutionize RA Treatment.....II-22
Branded Products.....II-22
1$100
   Drugs Used in Treating Rheumatoid Arthritis.....II-23
Year of Approval of Leading Biologics in Rheumatoid Arthritis Therapy.....II-23
Key Drugs in Late Stage Development for Rheumatoid Arthritis Treatment.....II-23
1$100
   Competitive Landscape.....II-24
Table 2: Comparative Analysis of Leading Biologic Rheumatoid Arthritis Drugs based on ACR Scores by End Point.....II-24
1$350
   High Prices and Safety Concerns.....II-25
Multiple Sclerosis.....II-25
Etiology.....II-25
1$100
   Types of Multiple Sclerosis.....II-26
Table 3: Prevalence of Different Types of Multiple Sclerosis.....II-26
Pathology.....II-26
1$350
   Prevalence of Multiple Sclerosis High in Women.....II-27
Facts About Multiple Sclerosis.....II-27
Treatment.....II-27
1$100
   Interferon Drugs - High Efficacy Drugs in Existing MS Therapies.....II-28
Beta Interferon Drugs in Multiple Sclerosis Treatment.....II-28
Non-Interferon Drugs.....II-28
1$100
   Non-Interferon Drugs in Multiple Sclerosis Treatment.....II-29
Trends in Multiple Sclerosis Market.....II-29
High Unmet Need and Rich Pipeline to Expand MS Market.....II-29
Interferon-based Drugs Lead Multiple Sclerosis Drug Market.....II-29
1$100
   Oral Drugs Alter Dynamics in MS Therapies Market.....II-30
Dip in Sales Inevitable for Current Therapies.....II-30
1$100
   Tough Times Ahead for Betaseron.....II-31
Competitive Landscape.....II-31
1$100
   Table 4: Leading Products/Companies in the Global Multiple Sclerosis Therapeutics Market (2010): Percentage Share Breakdown of Value Sales for Biogen Idec, Teva/sanofi-aventis, Merck Serono, Bayer Schering, Elan, and Others (includes corresponding Graph/Chart).....II-321$350
   Multiple Sclerosis Drug Pipeline – An Overview.....II-33
Drugs Under Development for Treating Multiple Sclerosis.....II-33
Fingolimod (Gilenya).....II-33
Mylinax.....II-33
1$100
   Laquinimod.....II-34
Campath (Alemtuzumab).....II-34
1$100
   Teriflunomide.....II-35
Fampridine-SR.....II-35
BG-12 (Oral Fumarate).....II-35
MN-166.....II-35
1$100
   Psoriasis.....II-36
Prevalence.....II-36
Available Treatment Options.....II-36
1$100
   Biological Drugs.....II-371$100
   Biological Drugs Lead the Fray.....II-38
Potential Therapeutic Products.....II-38
Inflammatory Bowel Diseases.....II-38
Crohn's disease.....II-38
1$100
   Stages of the Disease.....II-39
Prevalence.....II-39
Diagnosis.....II-39
Treatment.....II-39
2$200
   Ulcerative Colitis.....II-41
Diagnosis and Treatment.....II-41
Other Diseases.....II-41
Systemic Lupus Erythematosus (SLE).....II-41
1$100
   Prevalence and Epidemiology.....II-42
Treatment.....II-42
Sjogren's Syndrome.....II-42
1$100
   Prevalence and Epidemiology.....II-43
Diagnosis and Treatment.....II-43
1$100
   Type-1 Diabetes Mellitus.....II-44
Types of Diabetes Mellitus.....II-44
Type 1 or Insulin Dependent Diabetes Mellitus.....II-44
Type 2 or Non-Insulin Dependent Diabetes Mellitus.....II-44
Insulin – Vital for Blood Glucose Management.....II-44
1$100
   Etiology.....II-45
Prevalence.....II-45
Diabetes in Children - A Growing Concern.....II-45
Diagnosis and Treatment.....II-45
1$100
   Autoimmune Hepatitis.....II-46
Disease Categories.....II-46
Treatment.....II-46
Side Effects.....II-46
1$100
   Juvenile Rheumatoid Arthritis.....II-47
Symptoms.....II-47
Diagnosis.....II-47
Scleroderma.....II-47
1$100
   Prevalence.....II-48
Etiology.....II-48
Diagnosis.....II-48
Management.....II-48
Vasculitis Syndeomes.....II-48
1$100
   Haematologic Autoimmune Diseases.....II-49
Ankylosing Spondylitis.....II-49
1$100
   Antares Pharma Commences VIBEX MTX Clinical Trial for Treating Rheumatoid
  Arthritis.....II-50
Avila Therapeutics Introduces Btk Inhibitor for Treating Autoimmune Diseases and
  Cancer.....II-50
Athersys and Angiotech to Conduct MultiStem® Clinical Trial.....II-50
1$100
   BioMarin Commences Amifampridine Phosphate Clinical Trial for Treating LEMS.....II-51
TxCell Successfully Completes Trial for Crohn's Disease Cell Therapy.....II-51
Novartis Releases Phase II Data for AIN457.....II-51
Sanofi Releases Phase III TEMSO Study Results of Teriflunomide.....II-51
1$100
   Biogen Achieves Positive Results for BG-12 Drug Trial.....II-52
Innate Therapeutics Commences MIS416 Clinical Trial in Progressive MS Patients.....II-52
Pfizer Completes Clinical Trials for Tasocitinib.....II-52
1$100
   Compugen Completes Animal Model Study of CGEN-15001.....II-53
Avila Therapeutics Commences AVL-292 Clinical Trial.....II-53
1$100
   Horizon Pharma Completes Clinical Trials for LODOTRA®.....II-54
ChemoCentryx Begins Phase 1 Clinical trial for CCX168.....II-54
NYU Langone Medical Center Announces Potential Therapy for Rheumatoid
  Arthritis.....II-54
1$100
   Compugen to Start Preclinical Development for Therapeutic Drugs.....II-55
Avila Therapeutics Begins Phase I Clinical Trial for AVL-292.....II-55
1$100
   VBL Therapeutics Releases Preclinical Data for VB-201.....II-56
GlaxoSmithKline and Dynavax Select DV1179 for Endosomal TLR Inhibitor Program.....II-56
1$100
   Idera Pharmaceuticals Starts Phase 1 Clinical Study of IMO-3100.....II-571$100
   ChemoCentryx Begins Phase I Clinical Study of CCX168.....II-58
VBL Therapeutics Starts Phase II Clinical Study of VB-201.....II-58
1$100
   ChemoCentryx Begins Phase II Clinical Study of CCX354.....II-59
Neovacs Starts Phase IIa Clinical Study of TNF Kinoid.....II-59
1$100
   Galapagos Begins Phase II Clinical Study of Nanocort.....II-60
Plexxikon Starts Dosing of PLX3397 in Phase I Clinical Study.....II-60
2$200
   Horizon Pharma Receives FDA Approval for DUEXIS®.....II-62
Venus Remedies to Launch Trois.....II-62
CNRS/Inserm Researchers Introduce Dendrimer ABP as RA Therapy.....II-62
1$100
   Food and Drug Monitoring Agency to Approve Tocilizumab for Commercial Use.....II-63
Novartis Bags EC Approval for Gilenya®.....II-63
Genentech Obtains FDA Approval for ACTEMRA.....II-63
Novartis Gains Approval for Gilenya in Japan.....II-63
1$100
   Novartis Receives FDA Approval for Gilenya.....II-64
Compugen Discovers and Validates CGEN-15001 Soluble Recombinant Fusion Protein.....II-64
InNexus Biotechnology Develops IXSCD11a.....II-64
Centocor Ortho Biotech Submits sBLA for Simponi Label Extension.....II-64
1$100
   Osiris Therapeutics Obtains Orphan Drug Designation for Prochymal from FDA.....II-65
Immunomedics Obtains US Patent for Immunotherapy.....II-65
Biogen Idec Introduces Monoclonal Antibody Tysabri in India.....II-65
1$100
   Merck Serono Unveils Pre-Filled Pen RebiDose™ in UK .....II-66
BioMarin Unveils Firdapse™ in European Union.....II-66
Sandoz Introduces Calcipotriene Solution in US.....II-66
Cimzia® Receives FDA Approval for Treating Rheumatoid Arthritis.....II-66
1$100
   Simponi™ Receives FDA Approval for Treating Rheumatoid Arthritis.....II-67
Novartis Introduces Extavia® for Multiple Sclerosis Treatment in Denmark &
  Germany.....II-67
Novartis Bags FDA Approval for Extavia.....II-67
UCB Receives EC Approval for Cimzia.....II-67
1$100
   Centocor Ortho Biotech Receives FDA Approval for Stelara.....II-68
BioMarin Pharmaceutical Bags FDA’s Orphan Drug Designation.....II-68
Promius Pharma Introduces Scytera™ for Psoriasis Treatment.....II-68
Galderma Receives FDA Approval for Plaque Psoriasis Ointment Vectical™.....II-68
Roche Obtains EC Approval for Rheumatoid Arthritis Antibody RoACTEMRA.....II-68
1$100
   Viron Therapeutics Obtains US Patents for VT-384, VT-346 Candidates.....II-69
Bayer Schering Pharma Obtains Approval for Betafron® Therapy from SFDA.....II-69
US Food and Drug Administration Approves Certolizumab Pegol.....II-69
Nitec Unveils Lodotra® in Germany.....II-69
1$100
   HUMIRA® Obtains EU Approval for Polyarticular Juvenile Idiopathic Arthritis.....II-70
Cimzia® Receives FDA Nod for Treating Crohn’s Disease.....II-70
HUMIRA® Obtains Approval from Japanese Ministry for Rheumatoid Arthritis.....II-70
HUMIRA® Receives FDA Clerance for Polyarticular Juvenile Idiopathic Arthritis.....II-70
1$100
   Abbott Receives EU Marketing Authorization for Humira in Psoriasis Treatment.....II-71
Xian-Janssen Introduces Remicade, Branded infliximab in China.....II-71
HUMIRA® Obtains EU Approval for Treating Crohn’s Disease.....II-71
HUMIRA® Obtains FDA Approval for Crohn’s Disease.....II-71
Remicade® Obtains Approval for Use in PsA and Early RA in Australia.....II-71
1$100
   Tysabri™ Receives Health Canada Approval for Use in Multiple Sclerosis.....II-72
Rituxan® Gets FDA Approval for Use in RA.....II-72
1$100
   Humira® Obtains FDA Approval for Treating AS.....II-73
Betaseron® Receives FDA Approval for Use in First Clinical Episode of MS.....II-73
Abbott Receives FDA Clearance for HUMIRA Pen.....II-73
1$100
   Remicade Obtains FDA Approval for Treating Pediatric Crohn`s Disease.....II-741$100
   Sanofi-Aventis Takes over Genzyme.....II-75
Daiichi Sankyo to Acquire Plexxikon.....II-75
TiGenix Takes Over Cellerix.....II-75
Alkermes and Elan Drug Technologies to Merge Operations.....II-75
1$100
   Pfizer Japan Inks Agreements with Takeda to Co-Promote RA Drugs.....II-76
Viropro Inks Letter of Agreement with Spectrum Pharmaceuticals.....II-76
Pepscan Therapeutics Collaborates with Phylogica.....II-76
1$100
   Lycera Enters into Research Collaboration with Merck.....II-77
Merck Amends Distribution Agreement with Johnson & Johnson.....II-77
Yale University and Debiopharm Enter into License Agreement for Debio 1036.....II-77
Opexa Therapeutics Inks Agreement with American Red Cross.....II-77
1$100
   Antitope and NasVax Enter into Research Collaboration.....II-78
SuppreMol Inks In-License Agreement with Bayerische Patentallianz.....II-78
Glenmark Inks License Agreement with Sanofi.....II-78
1$100
   Exagen Enters into Partnership with Medco.....II-79
Phylogica Inks Research Collaboration and Option Agreement with Pepscan
  Therapeutics.....II-79
Merck Sharp & Dohme Enters into Partnership with Lycera.....II-79
1$100
   Amgen Enters into Collaboration with Xencor.....II-80
PhRMA Announces Development of Medicines Targeted Towards Women.....II-80
1$100
   Circassia Secures Global Development and Marketing Rights to PAP-1 from Airmid.....II-81
UCB Establishes Microbial Production Facility.....II-81
Emergent BioSolutions Takes Over Trubion Pharmaceuticals.....II-81
Gilead Sciences to Takeover CGI Pharmaceuticals.....II-81
1$100
   Abbott Laboratories Acquires Facet Biotech.....II-82
Merck Takes Over Millipore.....II-82
Quidel to Snap Up Diagnostic Hybrids.....II-82
1$100
   Nitec Pharma Merges with Horizon Therapeutics.....II-83
Femta Pharmaceuticals Inks Manufacturing Agreement with Lonza Group.....II-83
Horizon Pharma Signs Agreement with Mundipharma International.....II-83
3SBio Signs Agreement with Isotechnika Pharma.....II-83
1$100
   Fast Forward and Provid Pharmaceuticals Extend Partnership.....II-84
Antitope and PIKAMAB Collaborate.....II-84
Ligon Discovery Enters into Agreement with Lycera.....II-84
1$100
   Axxam, Fast Forward and Juvenile Diabetes Research Foundation Enter into
  Partnership.....II-85
GlaxoSmithKline Collaborates with ChemoCentryx.....II-85
Perseid Signs Agreement with Astellas Pharma for CTLA4-Ig Program.....II-85
Cellceutix Chooses Destum Partners for KM-133 Psoriasis Compound.....II-85
1$100
   NERC Commences Operations of IXO Therapeutics.....II-86
Avesthagen to Market Avent.....II-86
Isotechnika Pharma Divests Stake in Isodiagnostika.....II-86
1$100
   MacroGenics Obtains New Grants from NIH.....II-87
AnaptysBio Collaborates with VLST to Generate Novel Antibody Therapeutics.....II-87
AstraZeneca Enters into Exclusive License Agreement with Rigel Pharmaceuticals.....II-87
Immutep Inks License Agreement with GlaxoSmithKline for Therapeutic Antibody
  IMP731.....II-87
1$100
   Novo Nordisk Inks Research Collaboration Agreement with Combine.....II-88
Xention and Axxam Enter into Autoimmune Disorder Research Partnership.....II-88
Roche Takes Over Genentech.....II-88
Merck Acquires Schering-Plough.....II-88
1$100
   Pfizer Takes Over Wyeth.....II-89
Amgen Takes Over Immunex.....II-89
BioMarin Pharmaceutical Takes Over Huxley Pharmaceuticals.....II-89
Onyx to Takeover Proteolix.....II-89
Genzyme Takes Over Global Rights of Campath, Leukine and Fludara from Bayer.....II-89
1$100
   Bristol-Myers Squibb Enters into Agreement with Alder Biopharmaceuticals.....II-90
LEO Pharma Inks Agreement with Warner Chilcott.....II-90
Kineta One Acquires Commercial Rights for Compounds from Airmid.....II-90
1$100
   Kineta Signs Agreement with Alturas Analytics.....II-91
Catalyst Biosciences in Research and License Agreement with MedImmune.....II-91
Boehringer Ingelheimes Collaborates with Exelixis.....II-91
Lonza Signs Agreement with Opsona Therapeutics for Manufacturing Antibody.....II-91
1$100
   Eli Lilly and Incyte Enter into Agreement.....II-92
Novartis Option Fund and Avila Therapeutics Sign Option Agreement.....II-92
Genentech Acquires Rights for BHT-3021 from Bayhill Therapeutics.....II-92
Celentyx and Meiji Seika Kaisha Ink Agreement.....II-92
1$100
   Exelixis and Boehringer Ingelheim Enter into Autoimmune Disease Partnership.....II-93
Celldex Acquires Exclusive Rights of Immune-Stimulatory Molecules from Amgen.....II-93
Apitope and Merck Serono Sign Agreement for Multiple Sclerosis Drug.....II-93
Biovitrum and Affibody® Enter into Collaboration.....II-93
1$100
   Bayhill Therapeutics Bags Contract from Genentech.....II-941$100
   Novo Nordisk and VLST Collaborate on Therapeutic Targets Development.....II-95
Actemra’s Approval Gets Delayed.....II-95
1$100
   Apitope Raises Financing for Developing Multiple Sclerosis Compound.....II-96
CalciMedica to Acquire Rights to STIM1 from TorreyPines.....II-96
1$100
   Roche Acquires ARIUS Research, Inc......II-97
Astellas Inks Agreement with Maxygen for MAXY-4 Candidates.....II-97
1$100
   Carna and Caliper Life Sciences Ink Collaborative Supply Agreement.....II-98
Isotechnika Gets Back Worldwide Rights to Transplant Drug, Voclosporin.....II-98
Boehringer In-licenses Two Drug Targets from BioFocus.....II-98
1$100
   Bionomics Enters into a Development and Licensing Agreement with Merck Serono.....II-99
Nycomed Inks Agreement with Immunomedics for Veltuzumab.....II-99
1$100
   EpiVax Receives Grants from National Institutes of Health to Advance Epi-13.....II-100
Boehringer to Takeover Actimis.....II-100
1$100
   Antisoma Acquires Xanthus Pharmaceuticals.....II-101
Merrimack Acquires Funds for Developing Cancer and Autoimmune Disease
  Biologics.....II-101
BioSeek and Merck Sign Collaboration Agreement for Compound Evaluation.....II-101
1$100
   Questcor Amends Distribution Contract with US Distributor of Acthar.....II-102
ANP Completes Phase IIa Trial for Multiple Sclerosis Drug.....II-102
Insert and Calando Merge to Form Calando Pharmaceuticals.....II-102
1$100
   Codon Inks Research & Development and Licensing Deal with Merrimack.....II-103
Debiopharm Inks licensing Deal with Airmid for Debio 0824 ShK Peptide.....II-103
Chelsea Acquires Global Rights to I-3D Range of DHODH Inhibiting Compounds.....II-103
1$100
   Cypress Bioscience Acquires Proprius.....II-104
J&J PRD Grants Milestone Payment to Sunesis Pharmaceuticals.....II-104
1$100
   GlaxoSmithKline Acquires License to Market Vaccinex’s Antibody.....II-105
Teva to Takeover CoGenesys.....II-105
Hadasit, HMS and BWH to Co-develop Oral Therapy for Autoimmune Diseases.....II-105
Anthera Acquires Rights to Develop and Market AMG 623 from Amgen.....II-105
Can-Fite Enters into Two Cooperation Agreements to Develop CF102 Drug.....II-105
1$100
   Source MDx Inks an Agreement with Pfizer.....II-106
Cambridge Inks an Antibody Development Agreement with Medarex.....II-106
1$100
   Pfizer to Acquire Coley Pharma.....II-107
GSK Joins Hands with Tolerx to Develop and Commercialize otelixizumab.....II-107
1$100
   Amgen Acquires Avidia.....II-108
Eli Lilly and MacroGenics Tie Up for Developing Teplizumab.....II-108
1$100
   MorphoSys and Genesis Ink Antibody R&D Deal.....II-109
arGentis Enters into a License Agreement with UTRF.....II-109
Eden Biodesign to Investigate Novel Drug Candidate for Autoimmune Diseases.....II-109
1$100
   Nuon and Kissei Team up for Tranilast.....II-110
Organon and Dyax Team Up for Developing Therapeutic Antibodies.....II-110
Medarex Joins Hands with Mitsubishi for Monoclonal Antibody Development.....II-110
Merck and Archemix Collaborate.....II-110
1$100
   Genzyme Takes Over Bioenvision.....II-111
Organon and Medarex Ink Drug Development Deal.....II-111
CalciMedica Secures Exclusive Rights for CBR’s Autoimmune Drug Target.....II-111
1$100
   Xanthus Secures Exclusive Patent Estate Rights for FLT3 Pathway.....II-112
Eisai Corporation Acquires Morphotek.....II-112
TIRC Changes Name to Orchestra Therapeutics.....II-112
1$100
   Abbott Files HUMIRA® for Psoriasis in the US and EU (USA/Europe).....II-113
Accentia Secures Exclusive Global Rights to Revimmune.....II-113
1$100
   Medarex and Compugen Ink Collaborative Agreement for Therapeutic Antibody.....II-114
SRI and Telik Sign License Agreement for Drug Development.....II-114
1$100
   China Biopharma Signs Agreement with Chinese Biopharmaceutical Firm.....II-1151$100
   Kirin and Astellas Ink Licensing Agreement for Anti-CD40 Antagonistic mAb.....II-116
QSV and Artielle Sign Contract to Produce RTL-1000.....II-116
JDRF and MacroGenics Form Partnership.....II-116
1$100
   GSK and Genmad Sign Partnership Agreement for HuMaxCD20.....II-117
Biocon Enters into Joint Venture Agreement with Neopharma.....II-117
1$100
   Pipex Pharmaceuticals Acquires Remaining Stake in Effective Pharmaceuticals.....II-118
Astellas Acquires Worldwide Rights for Amevive®.....II-118
1$100
   Biogen Acquires Fumapharm.....II-119
Biogen and UCB Join Hands for Oral Multiple Sclerosis Therapy.....II-119
1$100
   Abbott Laboratories (USA).....II-120
Amgen Inc. (USA).....II-120
1$100
   Bayer Schering Pharma AG (Germany).....II-1211$100
   Biogen Idec Inc. (USA).....II-1221$100
   Bristol-Myers Squibb Company (USA).....II-123
Elan Corporation plc (Ireland).....II-123
1$100
   Eli Lilly and Company (USA).....II-1241$100
   F. Hoffmann-La Roche AG (Switzerland).....II-125
Chugai Pharmaceutical Co., Ltd. (Japan).....II-125
1$100
   Genentech, Inc. (USA).....II-1261$100
   GlaxoSmithKline Plc (UK).....II-1271$100
   Johnson & Johnson, Inc. (USA).....II-128
Merck & Co., Inc. (US).....II-128
1$100
   Merck Serono SA (Switzerland).....II-1291$100
   Novartis AG (Switzerland).....II-130
Sanofi-aventis SA (France).....II-130
1$100
   Shire Plc (Ireland).....II-131
Teva Pharmaceuticals Industries Limited (Israel).....II-131
1$100
   UCB S.A. (Belgium).....II-1321$100
   Table 5: World Recent Past, Current & Future Analysis for Autoimmune Disease Therapeutics by Geographic Region – US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-1331$350
   Table 6: World Historic Review for Autoimmune Disease Therapeutics by Geographic Region – US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1341$350
   Table 7: World 15-year Perspective for Autoimmune Disease Therapeutics by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-1351$350
   Table 8: World Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics (Biologics) by Geographic Region – US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-1361$350
   Table 9: World Historic Review for Rheumatoid Arthritis Therapeutics (Biologics) by Geographic Region – US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1371$350
   Table 10: World 15-year Perspective for Rheumatoid Arthritis Therapeutics (Biologics) by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-1381$350
   Table 11: World Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics by Geographic Region – US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-1391$350
   Table 12: World Historic Review for Multiple Sclerosis Therapeutics by Geographic Region – US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1401$350
   Table 13: World 15-year Perspective for Multiple Sclerosis Therapeutics by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-1411$350
   Table 14: World Recent Past, Current & Future Analysis for Psoriasis Therapeutics by Geographic Region – US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-1421$350
   Table 15: World Historic Review for Psoriasis Therapeutics by Geographic Region – US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1431$350
   Table 16: World 15-year Perspective for Psoriasis Therapeutics by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-1441$350
   Table 17: World Recent Past, Current & Future Analysis for Crohn’s Disease Therapeutics (Biologicals) by Geographic Region – US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-1451$350
   Table 18: World Historic Review for Crohn’s Disease Therapeutics (Biologicals) by Geographic Region – US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1461$350
   Table 19: World 15-year Perspective for Crohn’s Disease Therapeutics (Biologicals) by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-1471$350
   Table 20: World Recent Past, Current & Future Analysis for Other Autoimmune Disease Therapeutics by Geographic Region – US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-1481$350
   Table 21: World Historic Review for Other Autoimmune Disease Therapeutics by Geographic Region – US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1491$350
   Table 22: World 15-year Perspective for Other Autoimmune Disease Therapeutics by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-1501$350
   A. Market Analysis.....II-151
Current and Future Analysis.....II-151
Autoimmune Diseases Fact Sheet.....II-151
1$100
   Table 23: Prevalence of Key Autoimmune Diseases in the US (in Millions) (includes corresponding Graph/Chart).....II-152
Market Trends.....II-152
Biologic Drugs Lead the Fray.....II-152
Biologics To Add Further Impetus to the Market.....II-152
1$350
   Rheumatoid Arthritis Drugs Lead the Market.....II-153
Enbrel and Humira Continue to Gain Share in the Anti-TNF Market.....II-153
Increased Incidence and Rise in Drug Prices to Drive Growth in MS Market.....II-153
1$100
   Table 24: Leading Multiple Sclerosis Drugs in the US (2008): Percentage Share Breakdown of New Prescriptions Written for Avonex, Copaxone, Rebif, Betaseron, and Tysabri (includes corresponding Graph/Chart).....II-154
Incidence of Type 1 Diabetes Mellitus Endemic in White Youth.....II-154
Lialda’s Share Gaining Momentum in Ulcerative Colitis Drugs Market.....II-154
1$350
   Key Ulcerative Colitis Drugs Market in the US (2006).....II-155
Product Launches/Approvals.....II-155
6$600
   Strategic Corporate Developments.....II-16130$595
   Key Players.....II-1917$395
   B. Market Analytics.....II-198
Table 25: US Recent Past, Current & Future Analysis for Autoimmune Disease Therapeutics by Disease Segment – Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn’s Disease (Biologics) and Other Autoimmune Diseases Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-198
1$350
   Table 26: US Historic Review for Autoimmune Disease Therapeutics by Disease Segment – Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn’s Disease (Biologics) and Other Autoimmune Diseases Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1991$350
   Table 27: US 15-Year Perspective for Autoimmune Disease Therapeutics by Disease Segment – Percentage Breakdown of Dollar Sales for Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn’s Disease (Biologics) and Other Autoimmune Diseases for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-2001$350
   A. Market Analysis.....II-201
Current and Future Analysis.....II-201
Japanese Patients Exhibit Unique Efficacy & Safety Effects.....II-201
Product Launches/Approvals.....II-201
1$100
   Strategic Corporate Developments.....II-2021$100
   Key Players.....II-2031$100
   B. Market Analytics.....II-204
Table 28: Japanese Recent Past, Current & Future Analysis for Autoimmune Disease Therapeutics by Disease Segment – Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn’s Disease (Biologics) and Other Autoimmune Diseases Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-204
1$350
   Table 29: Japanese Historic Review for Autoimmune Disease Therapeutics by Disease Segment – Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn’s Disease (Biologics) and Other Autoimmune Diseases Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-2051$350
   Table 30: Japanese 15-Year Perspective for Autoimmune Disease Therapeutics by Disease Segment – Percentage Breakdown of Dollar Sales for Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn’s Disease (Biologics) and Other Autoimmune Diseases for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-2061$350
   A. Market Analysis.....II-207
Current and Future Analysis.....II-207
Europe – A Burgeoning Market for Autoimmune Disease Therapeutics.....II-207
Increasing Awareness to Drive Market Growth.....II-207
Low Penetration to Fuel Growth in European MS DMDs Market.....II-207
1$100
   Table 31: Prevalence of Key Autoimmune Diseases in Europe in Millions (includes corresponding Graph/Chart).....II-208
Lower Treatment Rate Bodes Huge Potential for the UK MS Drug Market.....II-208
Drugs Hindering Disease Progression to Gain Prominence.....II-208
Rising Demand for Rheumatoid Arthritis Drugs in Russia.....II-208
1$350
   Product Launches/Approvals.....II-2093$150
   Strategic Corporate Developments.....II-21210$295
   Key Players.....II-2226$295
   B. Market Analytics.....II-228
Table 32: European Recent Past, Current & Future Analysis for Autoimmune Disease Therapeutics by Disease Segment – Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn’s Disease (Biologics) and Other Autoimmune Diseases Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-228
1$350
   Table 33: European Historic Review for Autoimmune Disease Therapeutics by Disease Segment – Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn’s Disease (Biologics) and Other Autoimmune Diseases Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-2291$350
   Table 34: European 15-Year Perspective for Autoimmune Disease Therapeutics by Disease Segment – Percentage Breakdown of Dollar Sales for Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn’s Disease (Biologics), and Other Autoimmune Diseases for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-2301$350
   A. Market Analysis.....II-231
Current and Future Analysis.....II-231
Canada.....II-231
Canada – Highest Prevalence Rates for Multiple Sclerosis.....II-231
Sales of Biologics on the Rise in Canadian Rheumatoid Arthritis Drugs
  Market.....II-231
1$100
   Asia-Pacific.....II-232
Autoimmune Diseases Market in Asia-Pacific – An Overview.....II-232
Incidence of Multiple Sclerosis in India on the Rise.....II-232
1$100
   Overview of Rheumatoid Arthritis in Australia.....II-233
Table 35: Percentage Breakdown of Prevalence of Rheumatoid Arthritis in Australia by Age Group (includes corresponding Graph/Chart).....II-233
1$350
   Table 36: Percentage Breakdown of Prevalence of Rheumatoid Arthritis in Australia by Sex (includes corresponding Graph/Chart).....II-234
Overview of Irritable Bowel Diseases in Australia.....II-234
1$350
   Product Launches/Approvals.....II-2352$100
   Strategic Corporate Developments.....II-2374$200
   Key Player.....II-2412$150
   B. Market Analytics.....II-243
Table 37: Rest of World Recent Past, Current & Future Analysis for Autoimmune Disease Therapeutics by Disease Segment – Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn’s Disease (Biologics) and Other Autoimmune Diseases Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-243
1$350
   Table 38: Rest of world Historic Review for Autoimmune Disease Therapeutics by Disease Segment – Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn’s Disease (Biologics) and Other Autoimmune Diseases Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-2441$350
   Table 39: Rest of World 15-Year Perspective for Autoimmune Disease Therapeutics by Disease Segment – Percentage Breakdown of Dollar Sales for Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn’s Disease (Biologics) and Other Autoimmune Diseases for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-2451$350
    
 
 


Sales queries: Sales@StrategyR.com
Research queries: Info411@StrategyR.com